Valencell
Matthew Banet Ph.D. is currently a Senior Director of Research and Development at Baxter. Prior to this role, Matt founded toSense Inc.—a medtech company that Baxter purchased in April 2020—and served as the company’s President and Chief Scientific Officer. In this capacity, Dr. Banet helped develop the company’s novel wearable medical device—CoVaTM—and its measurements of stroke volume, cardiac output, heart rate, and respiration rate, all of which are made from the chest. Dr. Banet’s particular areas of expertise include: 1) development of innovative physiological measurements; 2) product design for medical devices; 3) optics; 4) drafting/prosecuting intellectual property; and 5) drafting/prosecuting regulatory filings. Prior to toSense, Matt founded three successful companies before the age of 40, and all in different industries. Dr. Banet received his Ph.D. from MIT and his undergraduate degree from University of California, San Diego. He is the named inventor on over 250 pending and issued patents.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Valencell
Valencell transforms the science of wearable biometrics to enable impactful health outcomes. Through innovative R&D and validated technologies, we develop breakthroughs and collaborate with wearables, hearables, and medical device companies around the world to deliver amazing results. With more than 85 granted patents and 100+ patents pending around the world, Valencell’s technology continuously and accurately measures real-time biometric and physiological data that powers meaningful consumer and patient insights. Valencell was founded in 2006 and headquartered in Raleigh, North Carolina. Investors include Halma, Sonion, TDF Ventures, GII TECH, and WSJ Joshua Fund.